Analysis for BDX

📈 Growth & Financial Trajectory

Over 8 quarters, BDX's revenue hovered around $5B with a peak near $5.89B in late 2025 and a shallow decline to about $4.71B by Q2 2026, a net decrease of roughly 5.5%. Net income swung, averaging positive earnings, with a notable quarterly loss in 2026 Q2 (-$311M) that offset several profitable quarters. The cumulative net income across the period remained solid (~$3.23B), indicating resilient profitability despite quarterly volatility.

💰 Margins & Cash Flow

Gross margin has been robust, around the mid-40s percent (roughly 41–48%) across quarters, supported by stable gross profit. Operating margins generally mid-to-high single digits to low teens, trending around 8–14% in several quarters, though the Q2 2026 loss tempered overall margin strength. Net cash flow from operating activities was consistently positive, typically in the hundreds of millions to around $1.36B in earlier quarters, while investing activity remained cash outflow; financing flows swung quarter to quarter. Free cash flow remained positive in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ran above $50B with liabilities near $29–30B and equity around $24–25B, implying a solid balance sheet with a modest debt load. Current assets versus current liabilities generally hovered near 1.0x, signaling reasonable liquidity but not a heavy cushion in all periods.

⚠️ Key Drivers & Risks

• Drivers: ongoing demand for healthcare devices, favorable cost management, and global expansion.
• Risks: quarterly earnings volatility (including a material quarterly loss in 2026), regulatory/country risk, and sensitivity to macro cycles and product pricing.